3F8
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Mouse |
| Target | GD2 |
| Clinical data | |
| Routes of administration | intravenous |
| ATC code | none |
| Identifiers | |
| CAS Number |
339169-93-6  |
| ChemSpider | none |
 (what is this?) (verify) | |
3F8 is a murine IgG3[1] monoclonal antibody which binds to GD2.[2]
It has been used in the detection and treatment of neuroblastoma.[3] For imaging neuroblastoma, it is labelled with one of the radioisotopes iodine-124 and iodine-131.[4][5]
See also
References
- ↑ Kushner BH, Cheung NK (1989). "GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma". Blood. 73 (7): 1936–41. PMID 2653466.
- ↑ "Sloan-Kettering - Neuroblastoma: 3F8 Monoclonal Antibody Therapy Q & A". Retrieved 2008-02-19.
- ↑ Weinstein, J. L. (1 June 2003). "Advances in the Diagnosis and Treatment of Neuroblastoma". The Oncologist. 8 (3): 278–292. doi:10.1634/theoncologist.8-3-278.
- ↑ Yeh SD, Larson SM, Burch L, et al. (1991). "Radioimmunodetection of neuroblastoma with iodine-131-3F8: correlation with biopsy, iodine-131-metaiodobenzylguanidine and standard diagnostic modalities". J. Nucl. Med. 32 (5): 769–76. PMID 1902508.
- ↑ Dauer LT, St Germain J, Williamson MJ, et al. (2007). "Whole-body clearance kinetics and external dosimetry of 131I-3F8 monoclonal antibody for radioimmunotherapy of neuroblastoma". Health Phys. 92 (1): 33–9. doi:10.1097/01.HP.0000231583.32904.6c. PMID 17164597.
This article is issued from Wikipedia - version of the 10/24/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.